查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1804262

止血剂的全球市场:各类型，各製剂，各用途，各终端用户，各流通管道，各地区 - 市场规模，产业动态，机会分析，预测(2025年～2033年)

Global Hemostats Market: Type, Formulation, Application, End Users, Distribution Channel, Region-Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025-2033
出版日期: | 出版商: Astute Analytica | 英文 227 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

止血剂市场与全球外科手术的步伐密切相关，反映了越来越多的外科手术对有效止血的需求日益增长。 2024 年，该市场规模约为 28.8413 亿美元，预计将稳定成长，到 2033 年将达到 48.3968 亿美元，2025 年至 2033 年的复合年增长率为 5.92%。推动这一增长的主要因素之一是微创手术技术（例如腹腔镜手术和机器人手术）的日益普及。

按地区划分，受益于完善的医疗基础设施和较高的手术量，北美继续在止血剂消费市场占主导地位。然而，亚太地区正在迅速崛起，这得益于政府资助的创伤网络的大量投资以及腹腔镜手术的激增，尤其是在中国和印度等人口大国。这种成长预示着市场格局的转变，并成为止血剂製造商的关键成长引擎，这些製造商正寻求利用亚太地区外科手术数量的成长和医疗保健覆盖面的扩大。

值得关注的市场发展

止血剂市场由强生、百特国际、辉瑞公司、贝朗公司和碧迪公司 (BD) 等主要参与者推动。这些产业领导者拥有强大的全球影响力，并始终致力于透过积极的研发、策略合作伙伴关係和持续的产品创新来提升其市场地位。

百特国际的内部应用止血实验室体现了这种创新驱动的方法，该实验室拥有一支由 50 名科学家组成的团队，致力于开发下一代止血解决方案。光是在2023年，该研究所就提交了42个专利家族，重点在于剪切稀化明胶和冷冻保护性凝血酶复合物等先进材料。这些创新旨在提高止血剂的有效性和多功能性，并满足现代外科手术的精细需求。

同时，BD正在透过收购策略性地扩展其产品组合，例如以2.14亿美元收购Tissuemed。此次收购使BD能够使用Tissuemed的超薄聚乙二醇贴片技术，从而拓宽其产品范围，并为市场提供更专业、更有效的止血选择。此举显示BD致力于透过创新产品的定向投资来巩固其市场地位。

关键成长动力

微创手术（MIS）数量的快速成长是推动止血剂市场扩张的最强因素。根据国际微创外科学会 (International Society for Micro-Invasive Surgery) 的数据，预计到 2024 年，全球将实施约 1.08 亿例腹腔镜、机器人和内视镜手术。与 2022 年相比，这一数字将增加约 1,100 万例，这表明微创外科技术 (MIS) 正在加速应用于各种外科手术。

目前，约三分之一的微创手术会使用止血钳，预计光在 2024 年就将使用约 3,600 万组止血钳。这种广泛的应用凸显了止血钳在实现安全且高效的 MIS 手术中发挥的关键作用。微创技术的持续发展预计将维持对止血钳产品的强劲需求，进一步推动市场创新和成长。

新的机会趋势

胶原蛋白-壳聚醣混合止血钳正引起越来越多的科学关注，这一趋势正在显着改变止血钳市场的竞争态势。这些混合製剂将胶原蛋白的有益特性与壳聚醣的独特性能相结合，从而提高了止血性能和组织相容性。 2023年1月至2024年3月，欧洲医疗器材资料库 (EUDAMED) 记录了11项新的胶原蛋白-壳聚醣混合产品CE标誌批准，而同期氧化纤维素基止血剂仅有3项批准。

本报告分析了全球止血剂市场，提供了每个细分市场的市场规模和预测、市场动态和趋势以及公司概况。

目录

第1章 调查架构

  • 调查目的
  • 产品概要
  • 市场区隔

第2章 调查手法

第3章 摘要整理:全球止血剂市场

第4章 全球止血剂市场概要

  • 产业价值链分析
    • 材料供应商
    • 厂商
    • 批发商
    • 终端用户
  • 产业预测
    • 天然来历的局部·外用止血生物材料
    • 合成来历的局部·外用止血生物材料
  • 大环境分析
  • 波特的五力分析
  • 市场动态和趋势
    • 成长促进因素
    • 课题
    • 主要趋势
  • COVID-19对市场成长趋势的影响的评估
  • 市场成长及预测
    • 市场收益的估计与预测(2020年～2033年)
    • 市场规模的估计与预测(2020年～2033年)
  • 竞争仪表板
    • 市场集中率
    • 企业的市场占有率分析(金额)(2024年)
    • 竞争製图

第5章 全球止血剂市场分析:各类型

  • 重要的知识见解
  • 市场规模与预测(2020年～2033年)
    • 局部止血剂
    • 其他

第6章 全球止血剂市场分析:各製剂

  • 重要的知识见解
  • 市场规模与预测(2020年～2033年)
    • 薄板·垫片止血剂
    • 海绵止血剂
    • 粉末止血剂
    • 矩阵·凝胶止血剂
    • 其他

第7章 全球止血剂市场分析:各用途

  • 重要的知识见解
  • 市场规模与预测(2020年～2033年)
    • 整形外科手术
    • 一般外科手术
    • 神经外科手术
    • 心血管手术
    • 重组手术
    • 妇产科手术
    • 其他

第8章 全球止血剂市场分析:各终端用户

  • 重要的知识见解
  • 市场规模与预测(2020年～2033年)
    • 医院
    • 门诊病人手术中心
    • 居家照护
    • 其他

第9章 全球止血剂市场分析:各流通管道

  • 重要的知识见解
  • 市场规模与预测(2020年～2033年)
    • 线上
    • 离线

第10章 全球止血剂市场分析:各地区

  • 重要的知识见解
  • 市场规模与预测(2020年～2033年)
    • 北美
    • 欧洲
    • 亚太地区
    • 中东·非洲
    • 南美

第11章 北美的止血剂市场分析

  • 重要的知识见解
  • 市场规模与预测(2020年～2033年)
    • 各类型
    • 各製剂
    • 各用途
    • 各终端用户
    • 各流通管道
    • 各国

第12章 欧洲的止血剂市场分析

  • 重要的知识见解
  • 市场规模与预测(2020年～2033年)
    • 各类型
    • 各製剂
    • 各用途
    • 各终端用户
    • 各流通管道
    • 各国

第13章 亚太地区的止血剂市场分析

  • 重要的知识见解
  • 市场规模与预测(2020年～2033年)
    • 各类型
    • 各製剂
    • 各用途
    • 各终端用户
    • 各流通管道
    • 各国

第14章 中东·非洲的止血剂市场分析

  • 重要的知识见解
  • 市场规模与预测(2020年～2033年)
    • 各类型
    • 各製剂
    • 各用途
    • 各终端用户
    • 各流通管道
    • 各国

第15章 南美的止血剂市场分析

  • 重要的知识见解
  • 市场规模与预测(2020年～2033年)
    • 各类型
    • 各製剂
    • 各用途
    • 各终端用户
    • 各流通管道
    • 各国

第16章 企业简介

  • B.Braun Melsungen AG
  • Baxter International Inc.
  • Becton Dickinson and Co.
  • Gelita Medical GmbH
  • Hemostatis LLC
  • Integra Life Sciences Holding Corp.
  • Johnson and Johnson
  • Medtronic PLC
  • Pfizer Inc.
  • Stryker Corp.
  • Teleflex Inc.
  • 其他的着名的企业
简介目录
Product Code: AA0724861

The hemostats market is closely tied to the pace of surgical activity worldwide, reflecting the growing demand for effective bleeding control in an expanding range of procedures. In 2024, the market is valued at approximately US$ 2,884.13 million and is forecasted to grow steadily, reaching an estimated valuation of US$ 4,839.68 million by 2033. This growth corresponds to a compound annual growth rate (CAGR) of 5.92% between 2025 and 2033. One of the key drivers behind this expansion is the increasing adoption of minimally invasive surgical techniques, such as laparoscopic and robotic surgeries.

Regionally, North America continues to dominate the hemostats market in terms of procedural consumption, benefiting from a well-established healthcare infrastructure and high surgical volumes. However, the Asia-Pacific region is rapidly gaining ground, propelled by significant investments in government-funded trauma networks and a surge in laparoscopic surgeries, especially in populous countries like China and India. This growth signals a shift in market dynamics as Asia-Pacific emerges as a vital growth engine for hemostatic product manufacturers seeking to capitalize on increasing surgical activities and expanding healthcare access in the region.

Noteworthy Market Developments

The hemostats market is led by several prominent companies, including Johnson & Johnson, Baxter International, Pfizer Inc., B. Braun SE, and Becton, Dickinson and Company (BD). These industry giants boast a strong global footprint and remain deeply committed to advancing their market positions through vigorous research and development efforts, strategic partnerships, and continuous product innovation.

Baxter International exemplifies this innovation-driven approach with its Applied Hemostasis laboratory, staffed by a team of 50 scientists dedicated to developing next-generation hemostatic solutions. In 2023 alone, this lab filed 42 patent families, focusing on advanced materials such as shear-thinning gelatin and lyoprotected thrombin combinations. These innovations aim to improve the efficacy and application versatility of hemostats, addressing the nuanced needs of modern surgical procedures.

Meanwhile, BD has strategically expanded its portfolio through acquisitions, exemplified by its purchase of Tissuemed for $214 million. This acquisition granted BD access to Tissuemed's ultra-thin polyethylene glycol patch technology, enhancing its product breadth and enabling it to offer more specialized and effective hemostatic options to the market. Such moves demonstrate BD's commitment to strengthening its position through targeted investments in innovative products.

Core Growth Drivers

The rapid growth in minimally invasive surgery (MIS) volumes stands out as the most powerful driver fueling expansion in the hemostats market. According to the International Society for Minimally Invasive Surgery, approximately 108 million laparoscopic, robotic, and endoscopic procedures are expected to be performed globally in 2024. This represents an increase of about 11 million cases compared to 2022, highlighting the accelerating adoption of MIS techniques across a wide range of surgical specialties.

Hemostatic agents are now deployed in roughly one out of every three minimally invasive surgeries, translating to nearly 36 million units utilized in 2024 alone. This widespread integration underscores the vital role hemostats play in enabling safe and efficient MIS procedures. The continued expansion of minimally invasive techniques is expected to sustain strong demand for hemostatic products, further driving innovation and growth within the market

Emerging Opportunity Trends

Scientific interest is increasingly shifting toward hybrid collagen-chitosan hemostats, a trend that is significantly reshaping the competitive dynamics within the hemostats market. These hybrid formulations combine the beneficial properties of collagen with the unique features of chitosan, offering enhanced hemostatic performance and improved tissue compatibility. Between January 2023 and March 2024, the European Database on Medical Devices (EUDAMED) recorded 11 new CE Mark approvals for collagen-chitosan composite products, a stark contrast to the mere three approvals granted for oxidized cellulose-based hemostats during the same period.

In the United States, the Food and Drug Administration (FDA) cleared six collagen-chitosan hybrid hemostats within the same timeframe. Notably, half of these products received Breakthrough Device designation, underscoring their innovative nature and clinical promise. These designations were largely based on rapid clot formation benchmarks demonstrated through preclinical testing, where bleeding times were reduced to under 20 seconds in porcine liver models.

Barriers to Optimization

Rising raw-material prices are significantly impacting profitability within the bovine-collagen-based biosurgicals segment, posing a substantial challenge to the hemostats market in 2024. According to data from the U.S. Department of Agriculture, the cost of medical-grade bovine tendon collagen surged to $19.40 per kilogram in April 2024, up sharply from $13.00 per kilogram in 2022. Although the amount of purified collagen used in each absorbable patch averages just 1.9 grams, this increase translates to a material cost of approximately $0.037 per unit.

Baxter's most recent 10-K filing highlights the financial strain caused by these raw material price hikes, reporting a $94 million year-over-year increase in biomaterial expenditures, driven predominantly by rising bovine collagen costs. This surge has compressed gross margins by roughly $6 per device, a notable figure that directly affects profitability. To counterbalance these increased costs, manufacturers have implemented price adjustments at the SKU level, with hospital group purchasing organization (GPO) catalogs reflecting average price hikes of around $9 per unit.

Detailed Market Segmentation

By Type, the topical category occupies a dominant position in the hemostats market, commanding over 85.46% of the total market share. This prominence is largely attributed to the versatility and convenience that topical hemostatic agents offer across a broad spectrum of surgical workflows. Unlike some hemostatic products that require specialized equipment or ancillary hardware, topical agents can be applied directly to the bleeding site with minimal preparation, making them highly compatible with both open surgeries and minimally invasive procedures.

By formulation, matrices and gels dominate the hemostats market in terms of formulation revenue, accounting for 34.26% of the total market share. Their popularity stems from their unique ability to combine the ease of handling typically associated with topical agents with the flexibility and adaptability of liquids. This hybrid quality makes them particularly well-suited for controlling bleeding in complex surgical fields where blood loss often originates from irregular cavities or delicate, friable parenchymal tissue.

Based on application, orthopedic surgery represents a significant segment of the hemostats market, capturing more than 30.26% of the total market share based on application. This prominence is largely due to the nature of orthopedic procedures, which tend to generate some of the heaviest routine blood loss among elective surgical specialties. As a result, orthopedic theaters are among the most intensive users of hemostatic products, relying heavily on these adjuncts to manage bleeding effectively during complex joint, spine, and trauma fixation surgeries.

By End Users, hospitals hold a commanding position in the hemostats market, capturing over 56.20% of the total market share. This dominance is primarily due to their responsibility for managing the highest acuity cases, which require a broad range of surgical consumables, including hemostatic products. Hospitals also exercise significant control over procurement formularies, enabling them to standardize and streamline the acquisition of essential items to meet the demands of complex surgical procedures.

Segment Breakdown

By Type

  • Topical Hemostats
    • Mechanical Hemostats
      • ORC Based
      • Gelatin Based
      • Collagen Based
  • Polysaccharide Based Topical Hemostats
    • Active Hemostats
    • Flowable Hemostats
  • Topical Thrombin Based Topical Hemostats
  • Others

By Formulation

  • Sheet and Pad Hemostats
  • Sponge Hemostats
  • Powder Hemostats
  • Matrix and Gel Hemostats
  • Others

By Application

  • Orthopedic Surgery
  • General Surgery
  • Neurological Surgery
  • Cardiovascular Surgery
  • Reconstructive Surgery
  • Gynecological Surgery
  • Others

By End User

  • Hospitals
  • Ambulatory Surgical Centers
  • Home Care
  • Others

By Distribution Channel

  • Online
  • Offline
    • Direct
    • Distributor

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • Western Europe
      • The UK
      • Germany
      • France
      • Italy
      • Spain
      • Rest of Western Europe
    • Eastern Europe
      • Poland
      • Russia
      • Rest of Eastern Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East & Africa (MEA)
    • Saudi Arabia
    • South Africa
    • UAE
    • Rest of MEA
  • South America
    • Argentina
    • Brazil
    • Rest of South America

Leading Market Participants

  • B.Braun Melsungen AG
  • Baxter International Inc.
  • Becton Dickinson and Co.
  • Gelita Medical GmbH
  • Hemostatis LLC
  • Integra Life Sciences Holding Corp.
  • Johnson and Johnson
  • Medtronic PLC
  • Pfizer Inc.
  • Stryker Corp.
  • Teleflex Inc.
  • Other Prominent Players

Table of Content

Chapter 1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

Chapter 2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Sources
  • 2.2. Quantitative Research
    • 2.2.1. Primary & Secondary Sources
  • 2.3. Breakdown of Primary Research Respondents, By Region
  • 2.4. Assumption for the Study
  • 2.5. Market Size Estimation
  • 2.6. Data Triangulation

Chapter 3. Executive Summary: Global Hemostats Market

Chapter 4. Global Hemostats Market Overview

  • 4.1. Industry Value Chain Analysis
    • 4.1.1. Material Provider
    • 4.1.2. Manufacturer
    • 4.1.3. Distributor
    • 4.1.4. End User
  • 4.2. Industry Outlook
    • 4.2.1. Topical and Externally Administered Hemostatic Biomaterials from Natural Sources
    • 4.2.2. Topical and Externally Administered Hemostatic Biomaterials from Synthetic Sources
  • 4.3. PESTLE Analysis
  • 4.4. Porter's Five Forces Analysis
    • 4.4.1. Bargaining Power of Suppliers
    • 4.4.2. Bargaining Power of Buyers
    • 4.4.3. Threat of Substitutes
    • 4.4.4. Threat of New Entrants
    • 4.4.5. Degree of Competition
  • 4.5. Market Dynamics and Trends
    • 4.5.1. Growth Drivers
    • 4.5.2. Challenges
    • 4.5.3. Key Trends
  • 4.6. Covid-19 Impact Assessment on Market Growth Trend
  • 4.7. Market Growth and Outlook
    • 4.7.1. Market Revenue Estimates and Forecast (US$ Mn), 2020 - 2033
    • 4.7.2. Market Volume Estimates and Forecast (000' Units), 2020 - 2033
  • 4.8. Competition Dashboard
    • 4.8.1. Market Concentration Rate
    • 4.8.2. Company Market Share Analysis (Value %), 2024
    • 4.8.3. Competitor Mapping

Chapter 5. Global Hemostats Market Analysis, By Type

  • 5.1. Key Insights
  • 5.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
    • 5.2.1. Topical Hemostats
      • 5.2.1.1. Mechanical Hemostats
        • 5.2.1.1.1. ORC Based
        • 5.2.1.1.2. Gelatin Based
        • 5.2.1.1.3. Collagen Based
      • 5.2.1.2. Polysaccharide Based Topical Hemostats
        • 5.2.1.2.1. Active Hemostats
        • 5.2.1.2.2. Flowable Hemostats
      • 5.2.1.3. Topical Thrombin Based Topical Hemostats
    • 5.2.2. Others

Chapter 6. Global Hemostats Market Analysis, By Formulation

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
    • 6.2.1. Sheet and Pad Hemostats
    • 6.2.2. Sponge Hemostats
    • 6.2.3. Powder Hemostats
    • 6.2.4. Matrix and Gel Hemostats
    • 6.2.5. Others

Chapter 7. Global Hemostats Market Analysis, By Application

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
    • 7.2.1. Orthopedic Surgery
    • 7.2.2. General Surgery
    • 7.2.3. Neurological Surgery
    • 7.2.4. Cardiovascular Surgery
    • 7.2.5. Reconstructive Surgery
    • 7.2.6. Gynecological Surgery
    • 7.2.7. Others

Chapter 8. Global Hemostats Market Analysis, By End User

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
    • 8.2.1. Hospitals
    • 8.2.2. Ambulatory Surgical Centers
    • 8.2.3. Home Care
    • 8.2.4. Others

Chapter 9. Global Hemostats Market Analysis, By Distribution Channel

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
    • 9.2.1. Online
    • 9.2.2. Offline
      • 9.2.2.1. Direct
      • 9.2.2.2. Distributor

Chapter 10. Global Hemostats Market Analysis, By Region

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
    • 10.2.1. North America
      • 10.2.1.1. The U.S.
      • 10.2.1.2. Canada
      • 10.2.1.3. Mexico
    • 10.2.2. Europe
      • 10.2.2.1. Western Europe
        • 10.2.2.1.1. The UK
        • 10.2.2.1.2. Germany
        • 10.2.2.1.3. France
        • 10.2.2.1.4. Italy
        • 10.2.2.1.5. Spain
        • 10.2.2.1.6. Rest of Western Europe
      • 10.2.2.2. Eastern Europe
        • 10.2.2.2.1. Poland
        • 10.2.2.2.2. Russia
        • 10.2.2.2.3. Rest of Eastern Europe
    • 10.2.3. Asia Pacific
      • 10.2.3.1. China
      • 10.2.3.2. India
      • 10.2.3.3. Japan
      • 10.2.3.4. South Korea
      • 10.2.3.5. Australia & New Zealand
      • 10.2.3.6. ASEAN
      • 10.2.3.7. Rest of Asia Pacific
    • 10.2.4. Middle East & Africa
      • 10.2.4.1. UAE
      • 10.2.4.2. Saudi Arabia
      • 10.2.4.3. South Africa
      • 10.2.4.4. Rest of MEA
    • 10.2.5. South America
      • 10.2.5.1. Argentina
      • 10.2.5.2. Brazil
      • 10.2.5.3. Rest of South America

Chapter 11. North America Hemostats Market Analysis

  • 11.1. Key Insights
  • 11.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
    • 11.2.1. By Type
    • 11.2.2. By Formulation
    • 11.2.3. By Application
    • 11.2.4. By End User
    • 11.2.5. By Distribution Channel
    • 11.2.6. By Country

Chapter 12. Europe Hemostats Market Analysis

  • 12.1. Key Insights
  • 12.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
    • 12.2.1. By Type
    • 12.2.2. By Formulation
    • 12.2.3. By Application
    • 12.2.4. By End User
    • 12.2.5. By Distribution Channel
    • 12.2.6. By Country

Chapter 13. Asia Pacific Hemostats Market Analysis

  • 13.1. Key Insights
  • 13.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
    • 13.2.1. By Type
    • 13.2.2. By Formulation
    • 13.2.3. By Application
    • 13.2.4. By End User
    • 13.2.5. By Distribution Channel
    • 13.2.6. By Country

Chapter 14. Middle East and Africa Hemostats Market Analysis

  • 14.1. Key Insights
  • 14.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
    • 14.2.1. By Type
    • 14.2.2. By Formulation
    • 14.2.3. By Application
    • 14.2.4. By End User
    • 14.2.5. By Distribution Channel
    • 14.2.6. By Country

Chapter 15. South America Hemostats Market Analysis

  • 15.1. Key Insights
  • 15.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
    • 15.2.1. By Type
    • 15.2.2. By Formulation
    • 15.2.3. By Application
    • 15.2.4. By End User
    • 15.2.5. By Distribution Channel
    • 15.2.6. By Country

Chapter 16. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 16.1. B.Braun Melsungen AG
  • 16.2. Baxter International Inc.
  • 16.3. Becton Dickinson and Co.
  • 16.4. Gelita Medical GmbH
  • 16.5. Hemostatis LLC
  • 16.6. Integra Life Sciences Holding Corp.
  • 16.7. Johnson and Johnson
  • 16.8. Medtronic PLC
  • 16.9. Pfizer Inc.
  • 16.10. Stryker Corp.
  • 16.11. Teleflex Inc.
  • 16.12. Other Prominent Players